Myriad presents data on BRACAnalysis CDx and HRD at 2014 ASCO Meeting

June 2, 2014

Myriad Genetics, Inc., has presented new data at the American Society of Clinical Oncology (ASCO) meeting, concluding tomorrow in Chicago, supporting the clinical efficacy of its BRACAnalysis CDx and HRD tests in predicting platinum-based therapy response for breast cancer patients. In a trial of 86 patients, the response rates to platinum-based therapies (carboplatin and cisplatin) for patients with deleterious mutations detected by BRACAnalysis CDx (the company’s proprietary companion diagnostic test for deleterious mutations and large rearrangements in the BRCA1 and BRCA2 genes) was 54.5%, versus only 19.7% in the non-carrier group.

Myriad is making progress toward the commercialization of BRACAnalysis CDx for poly ADP ribose polymerase (PARP) inhibitors, and several of Myriad’s commercial pharmaceutical partners have recently made announcements on the advancement and expansion of their PARP inhibitor programs.

Myriad has also presented data evaluating the ability of its proprietary HRD tumor test in terms of its ability to predict response among triple negative breast cancer patients. The combination of Myriad’s three homologous recombination deficiency (HRD) assays, including Loss of Heterogyzosity (LOH), Telomere Allelic Imbalance (TAI), and Large-Scale State Transition (LST), were highly correlated with patient response rates. Myriad representatives told ASCO attendees that these data highlight the likely utility of HRD as a more comprehensive companion diagnostic for DNA damaging agents.

In addition, Myriad announced a new 160-patient randomized study evaluating HRD as a biomarker for prediction of cisplatin and paclitaxel response in triple negative breast cancer patients at diagnosis. This is one of several ongoing clinical trials Myriad is conducting to confirm the predictive power of HRD in guiding platinum-based therapy. Myriad plans to present data later this year on HRD that will support an early access launch of the test in triple negative breast cancer patients in late fiscal year 2015. Read more about genetic testing products offered by Myriad.

Read more